There were two tumors, which demonstrated clear-cut 5′/3′-end NTRK2 (NSCLC) and NTRK3 (adult sarcoma) expression imbalances, but turned out to be NTRK rearrangement-negative by the TruSight RNA Fusion NGS panel. This evidence concerns the gene NTRK2 and sarcoma.